PROMETHEUS protocol: tailored lifestyle and nutraceuticals in 20 middle-aged-to-older participants
The PROMETHEUS abstract describes an 8-week feasibility and exploratory study in 20 middle-aged-to-older participants receiving a multimodal, personalised intervention; it reports planned outcomes and feasibility aims, not results. [1]
Automatic summary · not editorially reviewed
The key findings
PROMETHEUS is described as an 8-week feasibility and exploratory study including 20 middle-aged-to-older participants. [1]
At baseline, urolithin A, nicotinamide mononucleotide and/or multivitamin-multimineral were prescribed based on muscle mass, VO2 peak and cognitive performance. [1]
The study aims to investigate recruitment feasibility, safety, adherence and exploratory outcome trajectories, and to inform a later 12-month randomised controlled trial. [1]
The source at a glance
- Study type / format
- Clinical trial protocol described in an abstract (feasibility and exploratory study).
- Population / context
- 20 middle-aged-to-older participants in an 8-week feasibility and exploratory study.
- Summary based on
- Study abstract
- Original publication
- July 3, 2026
PROMETHEUS: 8-week feasibility study in 20 participants
The abstract describes PROMETHEUS as an 8-week feasibility and exploratory study within the XPRIZE healthspan semi-finalist competition. It includes 20 middle-aged-to-older participants. The intervention is multimodal and combines fundamental and augmented components. Fundamental components include sleep and dietary recommendations, supplementation with whey protein, creatine and fucoidan, supervised exercise with an exergaming component (dual-task cognitive-physical training), motivational interviewing and cognitive behavioural therapy.
Supporting source [1]
Personalisation by gerotype and interim response
The augmented intervention is further personalised based on predefined gerotypes, described as reflecting individual ageing patterns beyond chronological age. At baseline, urolithin A, nicotinamide mononucleotide and/or a multivitamin-multimineral were prescribed based on muscle mass, VO2 peak and cognitive performance. At mid-intervention, interventions were adjusted based on individual response, including dose escalation and/or adding ergothioneine for inadequate improvement in cognition. Primary outcomes include muscle strength and mass, immune function and cognitive performance, plus feasibility indicators such as adherence and trial completion. Secondary outcomes include other biological, clinical and digital biomarkers of ageing and qualitative indicators of motivation and personal values.
Supporting source [1]
Aims: recruitment feasibility, safety and exploratory trajectories
The abstract states the study aims to investigate recruitment feasibility, safety, adherence and exploratory outcome trajectories of this multimodal, personalised precision geromedicine protocol based on baseline characteristics and interim responses. The findings are intended to inform the design of a subsequent 12-month randomised controlled trial of personalised lifestyle and nutraceutical strategies, with the potential to incorporate repurposed pharmacological agents to optimise age-related health outcomes. The abstract reports no results, effect sizes or safety findings.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. No results, effect sizes, adverse events or follow-up data are reported. The described 12-month randomised controlled trial is a future plan, not a completed study.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Kuerec AH, Guan L, Wang W, Barros D, Alenezi WM, Grgic J, Wazny VK, Morwani-Mangnani J, Dotou M, Zhang D, Chen T, Wang J, Ong JYY, Tay JH, To-Anan N, Sotelo CR, Khan ADBN, Bruggink W, Nair SV, Sukor SABM, Rikka S, Sin RCY, Chong HM, Hashim FBM, Hameed SNBS, Hamid ABBA, Jin X, Fuster C, Chen Y, Milani A, Zhang C, Macary P, Singham TR, Sachaphibulkij K, Dunn M, Yi L, Maier AB. · europepmc.org · July 3, 2026